相关实验视频

Updated: Feb 28, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

术后辅助化疗±PD-1抑制剂用于局部发达的头部和部状细胞癌

Zhiqiang Wang¹, Qingqing He¹, Donghui Jiang²

¹Department of Radiotherapy Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.

Cancer reports (Hoboken, N.J.)

|February 27, 2026

概括

术后免疫疗法在与化学辐射疗法相结合时,对局部发达的头支状细胞癌 (HNSCC) 具有有限的附加益处. 虽然化学放射治疗比单独放射治疗改善了结果,但添加PD-1抗体并没有显著提高HNSCC患者的整体存活率或无进展存活率.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
头部和部癌症研究研究

背景情况:

针对局部晚期头支状细胞癌 (HNSCC) 的术后免疫疗法是一个需要进一步研究的领域.
当前局部发达HNSCC的治疗策略通常涉及手术后辅助疗法,但免疫治疗在这种情况下的作用尚未明确.

研究的目的:

评估术后免疫治疗在局部发达HNSCC的治疗中的价值和意义.
为了评估辅助化学放射治疗加PD-1抗体对生存结果的影响,与单独放射治疗和单独化学放射治疗相比.

主要方法:

分析了一组212名患有局部晚期HNSCC的患者,这些患者接受了彻底手术.
患者被分为三组:辅助放射治疗,辅助化疗放射治疗 (CRT) 和辅助化疗放射治疗加PD-1抗体 (PD-1 Ab).
对生存结果 (总生存 - OS,无进展生存 - PFS) 和预后因素进行了全面分析.

主要成果:

三年后的OS率为54.8% (放射治疗),75.4% (CRT) 和82.2% (CRT + PD-1 Ab).
无论是CRT和CRT + PD-1 Ab组,与单独放射治疗相比,都显示出更好的生存状况 (p < 0.05).
在CRT和CRT + PD-1 Ab组之间没有发现OS或PFS的统计学上显著差异 (p > 0.05). 年龄,吸烟史,TNM阶段和治疗方法是OS的独立预后因素.

结论:

与单独放射治疗相比,辅助化疗放射治疗显著改善了局部发达HNSCC的生存结果.
将PD-1抗体添加到化疗放射治疗中,在这个患者队列中没有提供统计学上显著的额外生存益处.
在已经对并发化疗或放射治疗反应良好的瘤中,PD-1抗体可能提供较少的益处.

关键词:

在 PD-1 Ab 中,辅助疗法是一种辅助疗法.头部和部状细胞癌瘤强度调节的辐射疗法.术后的免疫疗法.

更多相关视频

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...